Self-Study 2025 Release II Bundle

Type: Bundle•Format: On-demand

The 2025 BCOP Self-Study Bundle Release II offers 11 BCOP CE hours and ACPE CE hours. All self-study modules are on-demand and allow you to review and complete your learning at your convenience for up to one year following the release of the education.

This Self-Study Release II bundle contains the following modules:

  • Module 1: Review of CNS Prophylaxis in Adult Hematologic Malignancies
  • Module 2: Gene Therapy Advances in Hemophilia, Sickle Cell Disease, and Beta-Thalassemia
  • Module 3: The Four Body Problem: Four Drug Regimens in Newly Diagnosed Multiple Myeloma
  • Module 4: Updates in the Treatment of Hormone Receptor-Positive (HR+) Metastatic Breast Cancer
  • Module 5: Antibody Drug Conjugates (ADCs) in Solid Tumors

The modules may be completed in any order. Each contains an ACPE Pre-Test, Content Outline with accompanying articles, an ACPE and BCOP Post-Test, and a Course Evaluation. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.

Get the bundle

Course Learning Objectives

UAN#: 0465-0000-25-090-H01-P

Author: Justine Preedit, PharmD, BCOP

Learning Objectives

  1. Differentiate various CNS prophylaxis methodologies for hematologic malignancies, focusing on the route, timing, dose, and frequency of pharmacologic therapies
  2. Recognize disease-specific risk factors that increase the likelihood of CNS relapse in hematologic malignancies
  3. Explain the challenges and future directions of novel therapies for preventing CNS disease in hematologic malignancies
  4. Evaluate the efficacy and appropriateness of CNS prophylaxis in acute leukemias and large B-cell lymphomas

UAN#: 0465-0000-25-091-H04-P

Author: Jocelyn Mohs, PharmD, BCOP

Learning Objectives

  1. Describe gene therapies used in hemophilia and beta-thalassemia
  2. Evaluate efficacy and safety outcomes from completed gene therapy trials in hemophilia and beta-thalassemia
  3. Examine the cost-effectiveness and challenges for clinical use of gene therapies in hemophilia, sickle cell disease, and beta-thalassemia

UAN#: 0465-0000-25-092-H01-P

Author: Sara Gordon, PharmD, BCOP

Learning Objectives

  1. Interpret data evaluating four-drug treatment regimens for the treatment of newly diagnosed multiple myeloma
  2. Review the safety of four-drug regimens for patients with newly diagnosed multiple myeloma
  3. Develop a treatment plan for patients with newly diagnosed multiple myeloma based on transplant eligibility or minimal residual disease (MRD) status

UAN#: 0465-0000-25-093-H01-P

Author: Karen Abboud, PharmD, BCPS, BCOP

Learning Objectives

  1. Evaluate the role of imlunestrant with or without abemaciclib in estrogen receptor 1 (ESR1)-mutant metastatic breast cancer
  2. Identify patients who may benefit from inavolisib in combination with palbociclib-fulvestrant
  3. Demonstrate the appropriate place in therapy of trastuzumab deruxtecan in HR+ metastatic breast cancer
  4. Describe the efficacy and safety data of datopotamab deruxtecan in HR+ metastatic breast cancer

UAN#: 0465-0000-25-094-H01-P

Author: Joelyann Valles Rivera, PharmD, BCPS, BCOP

Learning Objectives

  1. Describe the structural components, key properties, the mechanism of action, and indications of available antibody-drug conjugates (ADCs)
  2. Apply recent advances in the use of datopotamab deruxtecan for the treatment of breast cancer
  3. Summarize the mechanisms and associated toxicities of ADCs
  4. Develop a plan for preventing, monitoring, and managing toxicities associated with ADCs
Spacer Image

Knowledge Courses for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post- Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.